The biopharmaceutical round table (BCR), which represents the main biopharmaceutical companies in the world, encountered in London.
April 04, 2025, London – This week, the Biopharmaceutical Round Table (BCR), which represents the main biopharmaceutical companies in the world, met the British Prime Minister, senior executives of the British cabinet and key officials to discuss the strengthening of global health policies and the maintenance of global political frameworks which lead to pharmaceutical innovation and Translation of scientific progress in drugs and vaccines.
The meeting was an opportunity to discuss the importance of creating the right environment to advance the shared ambition stated in the vision of the life sciences of the British government.
After the meeting with the British government, discussions also took place with the Prime Minister of Barbados, Hon. Mia Mottley MP on global health priorities.
Discussions have also focused on the importance of an effective intellectual property environment and solid and appropriate regulatory systems to stimulate innovation, as well as collaboration with stakeholders in the health care ecosystem to guarantee that drugs and vaccines reach patients.
Discussions have also highlighted the urgent need for policies that support a solid response in the fight against antimicrobial resistance. The pharmaceutical industry remains determined to provide access to essential antibiotics and work with global partners to develop economically sustainable solutions that allow rapid access to new antibiotics worldwide.
The president of the BCR, Dr. Thomas Schinecker, Managing Director Roche Group, said:
“Science changes the way we prevent, stop and heal the diseases – and the pharmaceutical industry is at the heart of this progress.
“Conversation with the British government has been a precious opportunity to focus on what really matters: how we create the conditions that allow innovation to prosper – and how we work together to make sure it reaches patients who need it.
“When we get things correctly, we do not only improve health care – we create a lasting value for patients, health systems and the wider economy.”
The secretary general of the BCR, Dr. David Reddy, director general of IFPMA, said:
“The pharmaceutical sector is a key engine of health and economic progress, and this meeting was an important opportunity to discuss how we can maximize our contribution to both.
“The unique engagement of our industry towards R&D, coupled with strong protections and intellectual property solutions that unlock access challenges, allows us to solve the urgent global health problems, from antimicrobial resistance to chronic diseases, while fueling economic growth and job creation worldwide”.
About IFPMA
IFPMA represents the innovative pharmaceutical industry at the international level, engaging official relations with the United Nations and multilateral organizations. Our vision is to ensure that scientific progress is reflected in the next generation of drugs and vaccines that offer a healthier future for people around the world.
To achieve this, we act as a trusted partner, bringing the expertise of our members to defend pharmaceutical innovation, stimulating the policy that supports the research, development and service of health technologies, and creating sustainable solutions that advance global health.